comparemela.com

Latest Breaking News On - Biologics license application - Page 4 : comparemela.com

First results from late-breaking Phase 3 PALOMA-3 study show five-fold reduction in infusion-related reactions with five-minute subcutaneous amivantamab administration

New formulation showed non-inferiority to intravenous administration in fourth positive Phase 3 study in RYBREVANT® clinical program

United-states
Toronto
Ontario
Canada
Chicago
Illinois
American
Prnewswire-johnson
Natashab-leighl
Johnson
None-of-janssen-research-development
Janssen-research-development

Jazz Pharmaceuticals Presents Overall Survival and Longer Follow-Up Data from HERIZON-BTC-01 Trial Evaluating Zanidatamab in Previously Treated HER2-Positive Biliary Tract Cancer at ASCO 2024

/PRNewswire/ Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced long-term follow-up results, including the first-ever overall survival (OS) findings,.

Germany
Texas
United-states
Ireland
Japan
Spain
Italy
China
France
Dublin
American
Kristin-bhavnani

ASCO 24: Data shows survival benefit with J&J's subcutaneous Rybrevant

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO

Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc. - ABEO
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

Tel-aviv
Israel
New-york
United-states
Chicago
Illinois
London
City-of
United-kingdom
Paris
France-general
France

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Abeona Therapeutics Inc.

/PRNewswire/ Pomerantz LLP is investigating claims on behalf of investors of Abeona Therapeutics Inc. ("Abeona" or the "Company") (NASDAQ: ABEO). Such.

London
City-of
United-kingdom
Paris
France-general
France
New-york
United-states
Tel-aviv
Israel
Chicago
Illinois

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.